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Abstract 
Psychostimulants such as mixed amphetamine salts (MAS, brand name Adderall) are widely used for 
cognitive enhancement by healthy young people, yet laboratory research on effectiveness has yielded 
variable results. The present study assessed the effects of MAS in healthy young adults with an 
adequately powered double-blind cross-over placebo-controlled trial. We examined effects in 13 
measures of cognitive ability including episodic memory, working memory, inhibitory control, convergent 
creativity, intelligence and scholastic achievement, with the goals of determining (1) whether the drug is 
at least moderately enhancing (Cohen's d >= .5) to some or all cognitive abilities tested, (2) whether its 
effects on cognition are moderated by baseline ability or COMT genotype, and (3) whether it induces an 
illusory perception of cognitive enhancement. The results did not reveal enhancement of any cognitive 
abilities by MAS for participants in general. There was a suggestion of moderation of enhancement by 
baseline ability and COMT genotype in a minority of tasks, with MAS enhancing lower ability participants 
on word recall, embedded figures and Raven's Progressive Matrices. Despite the lack of enhancement 
observed for most measures and most participants, participants nevertheless believed their performance 
was more enhanced by the active capsule than by placebo. We conclude that MAS has no more than 
small effects on cognition in healthy young adults, although users may perceive the drug as enhancing 
their cognition. 
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Abstract 
 
Psychostimulants such as mixed amphetamine salts (MAS, brand name Adderall) are widely 
used for cognitive enhancement by healthy young people, yet laboratory research on effectiveness has 
yielded variable results. The present study assessed the effects of MAS in healthy young adults with an 
adequately powered double-blind cross-over placebo-controlled trial.  We examined effects in 13 
measures of cognitive ability including episodic memory, working memory, inhibitory control, 
convergent creativity, intelligence and scholastic achievement, with the goals of determining (1) 
whether the drug is at least moderately enhancing (Cohen’s d >= .5) to some or all cognitive abilities 
tested, (2) whether its effects on cognition are moderated by baseline ability or COMT genotype, and 
(3) whether it induces an illusory perception of cognitive enhancement.  The results did not reveal 
enhancement of any cognitive abilities by MAS for participants in generalThere was a suggestion of 
moderation of enhancement by baseline abilityand COMT genotype in a minority of tasks, with MAS 
enhancing lower ability participants on word recall, embedded figures and Raven’s Progressive 
Matrices.  Despite the lack of enhancement observed for most measures and most participants, 
participants nevertheless believed their performance was more enhanced by the active capsule than by 
placebo. We conclude that MAS has no more than small effects on cognition in healthy young adults, 
although users may perceive the drug as enhancing their cognition. 
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1. Introduction 
 
Cognitive enhancement refers to the use of neuropsychological drugs, most commonly 
psychostimulants such as amphetamine and methyphenidate, by cognitively normal, healthy people to 
improve cognitive function. Evidence suggests that enhancement is a common practice and may be 
gaining in popularity. A study on a large 2001 sample of undergraduate programs including institutions 
of different size, location, religious affiliation and private/public status, showed an almost 7% lifetime 
prevalence of nonmedical stimulant use (McCabe, Knight, Teter & Wechsler, 2005). Although this 
study did not distinguish between cognitive enhancement and other nonmedical uses, more recent 
surveys of college students have done so and indicate that cognitive enhancement is the primary 
motivation for most students using stimulants (e.g., DeSantis, Webb, & Noar, 2008; see Smith & 
Farah, 2011, for a review).  These more recent studies also indicate substantially larger proportions of 
students using prescription stimulants compared to the McCabe and colleagues’ estimates, although the 
samples have been smaller and less representative.  Aside from college students, enhancement use of 
stimulants has also been reported among professionals from various fields (e.g., lawyers, journalists, 
Madrigal, 2008; Maher, 2008; Talbot, 2009).  
1.1.Stimulants’ Actual Cognitive Enhancement Effects 
One possible reason for the growing enhancement use of stimulants is that the drugs truly 
improve cognitive abilities such as learning and executive function, presumably through their effects 
on catecholamine neurotransmission (Meyer & Quenzer, 2005). Yet, in the aggregate, the evidence 
supporting stimulants’ beneficial effects on healthy cognition is mixed. For example, Chamberlain, 
Robbins, Winder-Rhodes, Muller, Sahakian, Blackwell and Barnett (2010) reviewed studies in which 
CANTAB tasks had been used to assess stimulant effects in patients and healthy control participants.  
They concluded that ―acute doses of medication improved aspects of cognition, though findings were 
more consistent in subjects with ADHD than in healthy volunteers.‖  Reviewing the literature on the 
cognitive effects of methylphenidate, Repantis, Schlattmann, Laisney & Heuser (2010) state that they 
were ―not able to provide sufficient evidence of positive effects in healthy individuals from objective 
tests.‖  Similarly, Hall and Lucke (2010) state that ―There is very weak evidence that putatively 
neuroenhancing pharmaceuticals in fact enhance cognitive function.‖ An even stronger view was 
presented by Advokat (2010), whose reading of the literature led her to suggest that ―studies in non-
ADHD adults suggest that stimulants may actually impair performance on tasks that require 
adaptation, flexibility and planning.‖  
Most recently, Smith and Farah (2011) surveyed more than fifty experiments on the effects of 
amphetamine and methylphenidate on a wide array of cognitive functions, including memory (episodic 
memory, procedural memory and probabilistic learning) and executive functions (working memory, 
cognitive control) in healthy young adults. They discovered a roughly even mixture of significant 
enhancement effects and null findings overall.  Studies on episodic memory tended to show an 
enhancing effect of stimulants when retention intervals were longer than an hour, whereas evidence for 
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enhancement of other functions was less clear.  For executive functions (including inhibitory control, 
working memory and other executive functions) many studies reported significant enhancing effects 
but some did not.  In addition, when found, these effects were sometimes qualified by complex 
interactions between the order of drug and placebo administration, participants’ cognitive performance 
on placebo, and participants’ genotypes. The possibility that other null results have been found but not 
published (publication bias, also known as the ―file drawer effect‖) must be considered. In sum, a 
number of recent reviews have concluded that the cognitive enhancement potential of stimulants has 
not received firm empirical support. 
Several factors may explain the inconsistency between users’ beliefs that stimulants enhance 
cognition and the equivocal evidence for these effects.  One possibility is that the assessment of 
enhancement effects in the laboratory has been impeded by problems such as unmeasured moderators, 
poor measurement of moderators or low statistical power.  These would be especially serious 
challenges to research in this area if the effects of stimulants are small and dependent on individual 
differences. Another possibility is that stimulants create a subjective perception of enhancement, 
possibly more salient and wide-spread than the actual effects.  The rest of this section will elaborate on 
these potential explanations. 
1.2.Challenges in Assessing the Enhancing Effects of Stimulants 
Among the challenges standing in the way of settling the question of stimulants’ enhancement 
potential are the following four.  The majority of published studies fail to meet any of these challenges, 
and no study has so far been designed to address all four. These challenges motivate the design of the 
present double-blind, placebo controlled, cross-over trial on the cognitive enhancement effects of 
mixed ampheramine salts (MAS, brand name Adderall). 
1.2.1.Moderation of enhancement effects by individual differences. One reason why 
previous research may have failed to detect significant evidence for enhancement is that stimulants 
may be effective for some individuals but not for others.  Thus, studies that have not measured or 
analyzed the effect of moderating individual differences may have erroneously concluded that the 
effects are small or nonexistent.   One candidate moderator is individuals’ endogenous dopamine 
activity. The relationship between dopamine activity and cognitive performance is believed to follow 
an inverted U-shaped curve, in which intermediate dopamine levels are optimal for cognitive 
performance, whereas low and high levels are detrimental (Robbins & Arnsten, 2009). Therefore, 
individuals at different starting points on this curve would benefit differentially from the increase of 
dopamine activity caused by a dose of stimulant. Individuals with sub-optimal baseline dopamine 
levels would be moved upward on the curve to higher cognitive performance.  By contrast, individuals 
with high baseline dopamine, standing at the peak or on the downward-sloping portion of the curve, 
would move downward in cognitive performance. 
Several studies have provided evidence for the moderation of stimulant effects by endogenous 
dopamine activity, as indexed by participants’ Catechol O-methyltransferase (COMT) genotype.  A 
common polymorphism of the COMT gene determines the activity of the COMT enzyme, which 
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breaks down dopamine and norepinephrine. Hence, the COMT genotype influences the level of 
synaptic dopamine. Mattay and colleagues (2003) have shown that individuals whose COMT genotype 
is associated with higher endogenous dopamine show less enhancement by amphetamine and in certain 
tasks may actually perform worse on the drug. 
Another possible moderator of amphetamine’s cognitive enhancing effects is cognitive ability. 
Several studies have found that participants who perform worse than average when on placebo are 
more likely to be enhanced by stimulants (Farah, Haimm, Sankoorikal & Chatterjee, 2008; De Wit, 
Crean & Richards, 2000; de Wit, Enggasser  & Richards, 2002, Mattay et al., 2000; Metha, Owen, 
Sahakian, Mavaddat, Pickard & Robbins, 2000). Findings of both COMT-moderated and performance-
moderated enhancement suggest that some of the null results in literature may result from a mixture of 
true enhancing effects for some individuals and absent or even reversed effects for others.  
Measurement of these two potential moderating factors is therefore crucial for determining the true 
enhancement potential of stimulant drugs.  In the present study we measure both.  
1.2.2.Regression to mean and measurement of baseline performance. Baseline 
performance, as a moderator of enhancement, has typically been indexed by performance on placebo.  
This measure is problematic because of the phenomenon of regression to the mean. To the extent that 
there is measurement error in the data, participants who score well in the placebo condition would be 
expected to score less well on average in a different session, and participants who score poorly in the 
placebo condition would be expected to score somewhat better on average in a different session.  
Consequently, even in the absence of moderation by baseline, placebo scores may appear to moderate 
the difference between drug and placebo purely due to regression to the mean. For this reason, we 
obtain a measure of baseline ability that is independent from participants’ performance on drug and 
placebo. 
1.2.3.Moderation by order of drug administration. Some previous within-subjects trials on 
the effects of stimulants on cognition have unexpectedly revealed a third moderator of enhancement 
effects. In particular, significant enhancement effects on three different tasks have been observed when 
the drug was administered before placebo, but not after (Elliott, Sahakian, Matthews, Bannerjea, 
Rimmer & Robbins, 1997). Such moderation is difficult to interpret; it might reflect a specificity of 
stimulant effects to novel tasks, or a specificity to more difficult tasks, or it may be a type II error.  If 
order is not controlled and analyzed in within-subjects studies, the effects of stimulants could be 
inflated or diluted.   Between-subjects studies are not free of this problem, as all participants 
effectively receive the drug or placebo first.  If stimulant effects are fleeting, then single-session 
between-subjects studies would overestimate the effectiveness of the drug.  Accordingly, in the present 
study we control for the order of drug administration both experimentally (i.e., by counterbalancing the 
variable between participants) and statistically. 
1.2.4.Statistical power. Insufficient statistical power to detect practically significant effects has 
been a major obstacle to discovering stimulants’ cognitive enhancing properties. Most of the 
experiments reviewed by Smith & Farah (2011) used samples of fewer than 40 participants, many with 
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between-subjects designs.  The present within-subject study’s sample size of 46 was chosen to give us 
95% power to detect a medium-size effect (Cohen’s d = 0.5) on any single measure. 
1.3.Perceptions of Enhancement 
Another way to explain the discrepancy between the rising enhancement use and the 
inconclusive empirical evidence for its effectiveness would be to hypothesize an inconsistency 
between stimulants’ perceived and actual effects on healthy cognition. Specifically, people may use 
stimulants for cognitive enhancement because they feel that the drugs improve their performance, even 
in the absence of actual effects. For this to be the case, two conditions need to be satisfied: first, 
participants must perceive their own performance as higher; second, they must attribute this higher 
performance to the drug. 
Addressing the former condition, a number of studies have asked whether self-estimation of 
performance increases as a function of stimulants. This idea was first considered by researchers in the 
middle of the 20
th
 century, motivated in part by concerns about amphetamine’s effect on the judgment 
of military personnel.  For example, Davis (1947) summarized his experience with British soldiers in 
World War II by writing that ―the subject who has taken amphetamine usually judges the effects more 
favorably than the experimenter.‖  Experimental evidence has provided converging support for this 
finding (Smith & Beecher, 1964; Hurst, Weidner & Radlow, 1967, despite a null finding in Baranski et 
al., 1997). In Smith & Beecher’s double-blind, placebo-controlled trial on amphetamine, participants 
took a calculus test.  Although they overestimated their performance in both conditions, the magnitude 
of overestimation was significantly greater in the amphetamine group.  In a recent study with 
modafinil, a nontraditional stimulant, Baranski, Pigeau, Dinich & Jacobs (2004) reported a trend 
toward more positive evaluation of performance with modafinil compared to placebo in a battery of 
cognitive tests.  The idea that drug effects on subjective assessment of performance may interfere with 
our ability to judge drug effectiveness for cognitive enhancement was raised more recently by Hall and 
Lucke (2010) who pointed out that, when taken by healthy people, stimulants may inflate self-
confidence, while failing to improve actual performance.  Although previous research has reported 
some evidence for amphetamine’s effects on self-evaluation, no research study, to our knowledge, has 
assessed whether participants specifically attribute this improved performance to the drug. Only if this 
is the case can the subjective drug effects explain the growing stimulant enhancement use in the 
absence of firm evidence for actual effects.  For this reason, in addition to measuring the objective 
effects of the MAS on cognitive performance, we also obtained rating of subjective perceptions of the 
effects of the ingested pills. 
1.4. The Present Study 
The purpose of the present double-blind, placebo-controlled, crossover study was to examine 
the actual and perceived cognitive enhancing effects of MAS on healthy young adults who were not 
sleep-deprived.  MAS is equivalent to the brand name drug Adderall, which has been characterized as 
the ―drug of choice‖ for cognitive enhancement among college students (DeSantis, Noar & Webb, 
2009).  We predicted that, relative to placebo, Adderall would improve performance on a wide range 
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of cognitive functions, including episodic and working memory, inhibitory control and creativity, as 
well as performance on tasks based on standardized tests. We further expected that low cognitive 
performers, as well as carriers of the val-val variant of the COMT gene would benefit from the drug 
more that high performers and met-met carriers, respectively. An alternative hypothesis was that MAS 
might evoke a subjective perception of enhancement, more salient than the drug’s actual enhancing 
effects. If substantiated, either of these predictions would provide a possible explanation of the 
growing psychostimulant use among healthy people. 
2. Materials and Methods 
 
2.1.Participants 
Participants were 46 Caucasian native English speakers (22 male and 24 female), aged 21-30 
(M age = 24, SD = 2.88), who responded to advertisements posted in the area of Drexel University and 
the University of Pennsylvania, as well as to email announcements at the University of Pennsylvania), 
inviting participation in tests of memory, creativity, intelligence and personality. Participants were 
excluded if they reported a history of medical conditions contraindicated for stimulant use, including 
any neurological or psychiatric disease, seizure disorder, high blood pressure, glaucoma, 
gastrointestinal blockage, heart disease, or thyroid problems.  Also excluded were participants using 
any other stimulants or substances that could interact with amphetamine, including addictive, 
psychoactive, neurological and blood-pressure drugs; anti-histamines; non-prescription dietary 
supplements; weight-loss pills, and caffeine consumption estimated to exceed 700mg/day.  Off-drug 
blood pressure measured to exceed 140/90 at the beginning of the study was another exclusion 
criterion because of the likelihood that the drug would increase blood pressure further.  Women who 
were pregnant or likely to become pregnant were not allowed to participate.  We also excluded 
potential participants who had previously used psychostimulant drugs to rule out sensitization (Paulson 
& Robinson, 1995) as an explanation for enhancement effects and tolerance (Schenk & Partridge, 
1997) as an explanation for a lack of such effects.  
2.2. Drug 
20 mg of mixed amphetamine salts (sulfate salts of dextroamphetamine and amphetamine, with the 
dextro isomer of amphetamine saccharate and d, l-amphetamine aspartate monohydrate, with d-amphetamine 
and l-amphetamine in 3:1 ratio) and placebo were administered in visually indistinguishable capsules. 
The selected dose is within the range of doses used in the enhancement literature, with some studies 
using lower doses, some higher, and some equivalent (Smith & Farah, 2011). The test drug was 
supplied by the University of Pennsylvania Investigational Drug Service.  
 
2.3.Tasks 
There were three versions of each task, to avoid repetition of items or trial orders across 
baseline, placebo and MAS conditions.  The three versions were of moderate and comparable difficulty 
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as determined by pilot testing.  One version was consistently used for the baseline condition while the 
other two versions were used equally often in the MAS and placebo conditions.  The 13 measures are 
listed in Table 1 and are described here. 
 
2.3.1.Memory. The consolidation of information into memory is central to learning and hence 
to academic and life success. Two tasks assessed memory with measures of verbal and visual 
recognition and verbal recall. 
2.3.1.1.Face Memory. In this test of episodic memory participants saw a sequence of 20 briefly 
flashed face images. Each stimulus was presented for 2250 ms, with an inter-trial interval of 750 ms. 
Encoding was followed by approximately two hours of cognitive testing, after which participants 
completed a recognition test. This test consisted of the 20 previously presented targets intermixed with 
20 new faces. Presentation duration and inter-trial interval at test were the same as those at the 
encoding phase. Our main dependent measure was number correct (total number correct out of total 
number of trials presented). 
2.3.1.2.Word Memory (two measures). Another test of episodic memory, this task presented 
participants with 25 words presented for 3s each with no intertrial interval.  After approximately two 
hours performing other cognitive tasks, two measures of word memory were then obtained.  In word 
recall, participants freely recalled as many words as possible.   Performance was measured as number 
recalled.  A word recognition test followed, in which participants viewed the 25 earlier words 
intermixed with 25 new words, presented in the same way as during encoding. The dependent measure 
in this case was number correct. 
 
2.3.2. Working memory. Working memory is an aspect of executive function that involves 
active short-term maintenance of information and is essential for many forms of thinking and problem-
solving.  Two tasks assessed verbal and visual working memory. 
2.3.2.1. Digit Span Forward and Backward (two measures). In this test of working memory, 
derived from a subtest of the Weschler Adult Intelligence Scale, the experimenter read digit sequences 
at a rate of approximately 1 digit per second and participants typed each sequence immediately after 
hearing it. In the Digit Span Forward task, 14 sequences were presented, with two each of lengths from 
2 to 8. Participants reported the digits in the order they heard them. In the Digit Span Backward 
condition, 14 different sequences of length 2-8 were presented and participants reported the digits in 
reverse order. The digit sequences gradually increased in length (from two to eight digits). A response 
was counted as correct only if all the digits within a sequence were reported correctly and in the correct 
order (i.e., no partial credit). Number correct for Digit Span Forward is generally viewed as a simple 
measure of maintenance capacity and Digit Span Backward as a measure of ability to simultaneously 
maintain and process information (The Psychological Corporation, 2002). 
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2.3.2.2. Object-2-Back. Object-2-Back tests the ability to maintain and update information in 
working memory despite interference (Postle, D’Esposito, & Corkin, 2003).  Participants saw a 
sequence of 155 random polygons, each flashed briefly, for duration of 1000ms. Interstimulus interval 
was 500 ms. Participants had to press a button every time the currently presented object matched the 
object two shapes back. The dependent variable was the number of omission errors, which is 
associated specifically with working memory ability in n-back tasks (Oberauer, 2005). 
 
2.3.3. Inhibitory control. The ability to withhold a habitual response or resist distraction by a 
salient stimulus is important for enabling us to act appropriately in many contexts.  Two tasks assessed 
inhibitory control over responses and stimuli. 
2.3.3.1. Go/No-go.  Go/No-Go is a test of inhibitory control (see Braver, Barch, Gray, Molfese 
& Snyder, 2001), in which participants viewed a sequence of briefly flashed digits 1-9 (stimulus 
duration: 300ms; interstimulus interval: 400ms). Participants were asked to press a key as quickly as 
possible in response to all digits except for the digit 4. The digit 4 appeared on 15% of the 200 trials. 
For this task, the only opportunities for inhibitory control failure occur on the ―4‖ trials and therefore 
the dependent measure was the number of commission errors (i.e., the number of trials on which 
participants failed to withold a response to the ―4‖; Helmers et al., 1995).  
2.3.3.2. Flanker. This test of inhibitory control (Eriksen & Eriksen, 1974) presented 
participants with 200 images of five horizontally aligned arrows. Participants were instructed to 
indicate as quickly and accurately as possible the direction (left or right) of the central arrow. In 
congruent trials, all arrows pointed in the same direction. In incongruent trials, the middle arrow 
pointed in a direction opposite to that of the peripheral arrows. The sequence consisted of an equal 
number of congruent and incongruent stimuli. Each stimulus remained on the screen until the 
participant responded; the response initiated a 1s blank screen before the next stimulus appeared. The 
measure of inhibitory control, termed here inhibition cost, was the ratio of the median reaction time of 
incongruent trials to the median reaction time in response to congruent trials. 
 
2.3.4. Creativity. Creativity is often defined as the ability to recombine familiar concepts in 
new and useful ways.  It has been operationalized with tasks that require participants to find 
associations among disparate concepts and to view complex visual patterns in alternative ways.  The 
two tasks used here were previously used by us in a study of the effects of MAS on creativity (Farah, 
Haimm, Sankoorikal, Smith & Chatterjee, 2008).  
2.3.4.1. Remote Associations Test. In this test of convergent creativity (Mednick, 1962) 
participants must generate the word which associates a group of three other words. For example, 
presented with the stimulus triad ―round – manners – tennis,‖ they had to answer ―table.‖ The test 
included 15 triads, for each of which participants had 30 s to respond. The dependent measure was 
number correct. 
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2.3.4.2. Group Embedded Figures Task. Another measure of convergent creativity (Noppe, 
1996) this test presented participants with complex geometric designs and a smaller element from the 
design. Within each larger design participants had to find and trace the specificed target element, 
which is ―embedded,‖ that is, not immediately apparent, given the overall visual gestalt of the design.  
An example is shown in Figure 1. Participants completed 6 items within a 2-minute time-limit for the 
whole test. The dependent measure was number correct. 
 
2.3.5. Standardized tests. Among the many standardized tests of intelligence and achievement 
are Raven’s Advanced Progressive Matrices, a nonverbal test of fluid intelligence, and the Scholastic 
Achievement Test (SAT), taken by college applicants in the US.  The two tasks here were composed of 
individual items taken from these standardized tests. 
2.3.5.1. Raven’s Advanced Progressive Matrices.  In this test of nonverbal intelligence (Raven, 
1976) participants saw a series of abstract patterns, each of which had a missing piece. Participants had 
to choose the best fitting piece from 6 options.  Each version of the test consisted of 12 items. 
Completion time for the whole test was limited to 10 min. The measure of interest was number correct. 
2.3.5.2. Scholastic Achievement Test (SAT; two measures).  This standardized test includes 
sections assessing ―critical reading,‖ ―writing‖ and ―mathematics.‖  We selected questions from a book 
of practice tests and grouped them into two sections, ―Verbal‖ and ―Math.‖  The former consisted of 
48 multiple-choice questions completed under a 40-minute time limit.  Question types (and 
corresponding number of questions) were as follows: Sentence Completion (7), Reading 
Comprehension (26), Improving Sentences (9), Identifying Sentence Errors (6). The Math section 
consisted of 27 questions (19 in multiple-choice and 8 in free-response format) testing algebra, 
geometry and other miscellaneous high-school-level problems, to be completed under a 28-minute 
time limit without the use of a calculator.  The measures of interest for SAT-Verbal and SAT-Math 
were number correct. 
 
2.3.6. Perceived drug effect. Perceived effect was examined through the following self-report 
prompt: ―The following question refers to all tests completed TODAY. How and how much did the 
drug influence (either positively or negatively) your performance on the tests? Please use the scale 
below. You answer can be any number between 1 and 100." The scale referred to was a line, ranging 
from 1 to 100, and labeled as follows: 1 = ―the drug impaired my performance extremely‖; 25 = ―the 
drug somewhat impaired my performance‖; 50 = ―the drug had no effect‖; 75 = ―the drug somewhat 
improved my performance‖; 100 = ―the drug improved my performance extremely. 
 
2.4. Procedure 
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The study took place over seven sessions, which included consent and practice (Session 1), 
followed by the full battery of cognitive tasks, for the baseline (i.e., no pill), placebo and MAS 
conditions (Sessions 2-7).  Baseline testing (Sessions 2-3) always preceded drug/placebo testing 
(Sessions 4-7) to minimize the influence of practice effects on data from the placebo and MAS 
conditions. During on-pill Sessions 4-7, the order of drug administration was counterbalanced, in a 
way that 24 participants received MAS in Sessions 3 and 4, and 22 participants received the drug in 
Sessions 6 and 7 The timeline of the study, including session sequence and timing, is presented in 
Figure 2.  
2.4.1. Session 1: Intake interview, instructions and practice. The first session consisted of 
consent procedure, followed by practice versions of the actual tests. The practice tests were identical to 
the experimental versions, except for comprising of fewer trials and different items. At the end of the 
session, participants were instructed to abstain, for the rest of the study, from drugs containing 
stimulants or interacting with stimulants (or to notify the study personnel if they had to take such 
drugs). Participants were also asked to avoid heavy meals on test days. 
2.4.2. Session 2 and 3: Baseline testing. Sessions 2 and 3 provided a measure of unmedicated 
(off-drug, off-placebo) performance.  The placebo condition was not used as a measure of baseline, so 
that regression to the mean would not be mistaken for moderation by cognitive ability.  
After the initial blood pressure measurement, participants completed an SAT test (one Verbal 
and one Math section) and a battery of cognitive tests (described above), respectively in Session 2 and 
3. These baseline tests were a version of the to-be-administered on-pill battery.  
2.4.3. Sessions 4-7: Testing on drug and placebo. The goal of these four sessions was to 
measure participants’ cognitive performance on MAS and on placebo. At the onset of these sessions, 
participants reported the amount of sleep and caffeine consumption during the previous 24 hours. They 
answered questions on their diet and medication intake to determine compliance with earlier 
instructions and had their blood pressure measured at the beginning and end of these sessions. 
Participants  also underwent a urine drug test to corroborate self report and deter use of excluded drugs 
(amphetamine, cocaine, barbiturates, benzodiazepine, phencyclidine and tetrahydrocannabinol). 
Female participants were administered a urine pregnancy test.  Participants with positive results on any 
of these tests were excluded. After an initial blood pressure measurement (participants were excluded 
if the measurement exceeded 140/90), participants were randomly assigned to take either MAS (20mg) 
or a visually indistinguishable placebo capsule in a double-blind manner. A 75-minute waiting period 
followed. We chose this interval to ensure that the peak drug plasma level, which is reached 2-3 hours 
after administration (Angrist et al., 1987) would occur during the testing. During the waiting time 
participants remained in the testing area and either read student periodicals or watched documentary 
DVDs (no homework or exciting movies were allowed).  Five minutes before testing (70 minutes after 
drug intake), blood pressure was taken again and participants were excluded if the measurement 
exceeded 150/100. In sessions 4 and 6 the battery of tests included personality, mood and attributional 
style questionnaires (not relevant to cognitive enhancement and therefore not discussed further here) 
and test materials assessing verbal and mathematical abilities from the SAT.  In sessions 5 and 7 the 
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remaining cognitive tests were administered, in the same order for all participants. The two 
nonbaseline versions of the tasks were counterbalanced with both drug condition (MAS, placebo) and 
session order. After the cognitive battery (sessions 5 and 7) participants reported their perception of the 
pill’s influence on their performance using the scale described earlier. At the end of the session, 
participants were reminded of the restriction on caffeine use and heavy-meal consumption for the rest 
of the study. If finishing the study, participants were thanked and paid. 
2.6. Data Analysis Approach 
2.6.1. Outlier removal.  
We removed outliers by excluding individual scores 3 SD above or below the mean of either 
the drug, placebo or baseline on each cognitive and subjective measure. If, on a particular measure, an 
individual participant’s baseline, drug, or placebo score met the criterion for an outlier, we excluded all 
the data (i.e., MAS, Placebo and baseline) of this participant from analyses of that same task. This led 
to the exclusion of a total of 22 data points, or .85% of all data.  
2.6.2. Missing Data.  
143 task performance measures (or 5.55% of all data) were missing due to technical problems 
(50 data points), evidence of participants’ failure to understand the task instructions (9 data points), or 
experimenter error (84 data points). 
 2.6.3. Statistical Tests 
 In overview, our approach to statistical testing was based primarily on mixed model analysis of 
variance (ANOVA) with drug (MAS or placebo) as a within-subjects factor and drug order and test 
version order as between-subject factors.  Multivariate analysis of variance (MANOVA) was used to 
assess the effects of drug across all 13 measures of cognitive ability and ANOVA to assess drug effects 
on each individual measure of cognitive ability and on ratings of perceived enhancement.  Moderation 
of cognitive enhancement by baseline ability and COMT genotype was tested within the same 
framework.  We also use multivariate regression and simple bivariate correlation in order to test two 
specific relations involving non-categorical factors (the moderating effect of COMT val load and the 
relation between perceived and actual enhancement).  All analyses were conducted in SPSS 20. The 
significance threshold was set to the standard cutoff of .05.  Results are reported without correction for 
multiple comparisons, a lenient approach that maximizes our ability to identify positive results at the 
risk of increasing possible false positive results. 
 
3. Results 
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3.1.Effects of Mixed Amphetamine Salts 
Table 2 shows the means and standard deviations of performance in each task for the baseline, 
placebo and MAS conditions. To examine whether cognitive performance differed between MAS and 
Placebo sessions, we conducted a 2(Drug: MAS; Placebo) x 2 (Drug Order: MAS first; Placebo first) x 
2 (Test Version Order: Version 1 first; Version 2 first)
 
mixed-model MANOVA with repeated 
measures on the first factor. The dependent variables were scores for 13 measures (listed in Table 
1).On this test, the difference between MAS and placebo performance did not reach significance (F 
(13, 13) = 1.71, p = .17), indicating that there was no overall enhancing effect of MAS on cognitive 
performance in the tasks.  We also failed to observe any significant two-way interaction between the 
drug conditions and either the drug order or the version order: (F (13, 13) = .59, p = .83; F (13, 13) = 
1.28, p = .33, respectively).  The absence of a Drug x Drug Order interaction indicates that MAS is no 
more or less enhancing when taken before or after the placebo session.  However, given the inclusion 
of a Baseline condition before all MAS and placebo conditions, these results do not rule out the 
possibility that MAS could enhance performance with novel tasks.  A marginally significant three-way 
(Drug x Drug Order x Version Order) interaction was observed (F (13, 13) = 2.14, p = .09). This 
interaction, which indicates differential drug effects on different versions of the tasks depending upon 
the order in which they were performed, does not lend itself to any obvious interpretation.  The 
possibility that the versions differed in difficulty, and the order in which they were encountered 
synergistically compounded these difficulty differences, is not supported by a comparison of 
performance across versions from placebo conditions. 
Although we began by testing the multivariate hypothesis that MAS would enhance overall 
performance across tasks, we also had a priori hypotheses about MAS effects on each of the 13 
measures obtained in the project.  We therefore followed up the MANOVA with a series of univariate 
2 (Drug: MAS; Placebo) x 2 (Drug Order) x 2 (Test Version Order) mixed-model ANOVAs with 
repeated measures on the first factor. These analyses tested the effect of MAS on each of the 13 
cognitive measures listed in Table 1. Again, these analyses revealed no effects of MAS and no two-
way interactions between drug and order or drug and version for any of the 13 measures. The three-
way interaction trend noted above emerged as significant (without correction for multiple 
comparisons) for five of the thirteen measures: Face Recognition, Flanker, Remote Associations, 
Embedded Figures, SAT Math. All main effects and interactions are shown in Table 1. 
Faced with null results for the effect of MAS on cognitive performance in these tasks, we asked 
whether differences in participants’ sleep prior to the MAS and placebo test days could have obscured 
the drug’s enhancing effect.  Self-reported sleep duration did not differ significantly between the 
sessions (t (41) = .91, p = .37 for neurocognitive testing sessions; t (45) = .74, p = .47 for SAT 
sessions), and showed a trend in the opposite direction to that hypothesized here, toward more sleep 
before MAS test sessions (M = 7.12, SD = 1.26 for neurocognitive testing sessions; M = 7.15, SD = 
1.30 for SAT sessions) than placebo (M = 6.89 h, SD = 1.53 for neurocognitive testing sessions; M 
=6.98, SD = 1.45 for SAT testing sessions). 
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3. 2. Moderation of MAS Effect by Baseline Performance 
To determine whether MAS enhances cognition for some people, with an effect that is 
moderated by baseline cognitive performance, we first separated participants into two groups 
according to whether their baseline performance was above or below the median and then conducted a 
series of 2 (Drug: MAS; Placebo) x 2 (Baseline Performance: Below-Median; Above-Median) x 2 
(Drug Order) x 2 (Test Version Order)
 
mixed-model ANOVAs with repeated measures on the first 
factor for each of the 13 cognitive performance measures. (MANOVA was not carried out because 
different participants fall in the upper and lower groups for different measures).  Significant 
interactions between drug and baseline performance emerged on two measures: Word Recall (F (1,36) 
= 4.78, p = .04) and, replicating our earlier study of MAS effects on this task (Farah et al., 2008), 
Embedded Figures (F (1, 28) = 8.48, p < .01). There was also a marginal trend toward significance for 
Raven’s Progressive Matrices ( F (1,29) = 2.83, p = .10).  In all three cases, the pattern of means was 
consistent with the prediction, based on the literature discussed earlier, of relatively more enhancement 
for the lower performing participants.  As shown in Figure 3, MAS tended to improve performance for 
the below-median baseline performers, while acting in the opposite direction for the above-median 
performers.   
In addition to comparing the effects of MAS between higher and lower performing participants, 
we can also ask whether low performers, the subgroup exclusively expected to benefit from the drug, 
shows enhancement. This question was addressed by a series of 2 (Drug: MAS; Placebo) x 2 (Drug 
Order: MAS first; Placebo first) x 2 (Test Version Order: Version 1 first; Version 2 first)
 
mixed-model 
ANOVAs with repeated measures on the first factor for each of the 13 measures only among the 
subsample performing below the median on baseline.  The effect of the drug was significant on Word 
Recall (F (1, 16) = 6.71, p = .02, Embedded Figures (F (1, 12) = 8.41, p = .01; and Raven’s 
Progressive Matrices (F (1, 16) = 5.36, p = .03). None of the remaining measures showed evidence of 
enhancement for the lower performing participants. See Supplementary Table 1 for other results 
which, because extraneous to our prediction, are not discussed further.  
 
3.3. Moderation of MAS Effect by COMT Genotype.   
Given the findings reviewed earlier of moderation of amphetamine enhancement effects by 
COMT genotype, we divided participants into three groups depending on whether they had val-val, 
val-met, or met-met alleles of COMT.  Because a MANOVA using genotype as a 3-level factor would 
not capture the ordering among the three groups we instead employed three alternative sets of analyses. 
First, we conducted a regression analysis, which included val load, drug order and version 
order to predict a composite of the differences between MAS and placebo.  The overall model was not 
significant, p = 0.28.  Second, we carried out thirteen additional regressions to examine the effects of 
val load, drug order and version order on MAS effect (i.e., drug minus placebo score) on each separate 
measure. Overall regression models for SAT Math and Verbal were marginally significant (F (3,43) = 
2.52, p = .07; F (3,43) = 2.25, p = .10, respectively). On SAT Math, the effect of COMT was 
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significant (b = .35, t = 2.38, p = .02); this effect was near significant on SAT Verbal (b = .24, t = 
1.64, p = .11). The patterns of means complied with the prediction that people with val-val genotype 
are more susceptible to enhancement than those with met-met genotype (see Figure 4).  
Third, we used MANOVA to contrast the effects of MAS on the two groups of homozygous 
participants with a 2 (Drug: MAS; Placebo) x 2 (COMT genotype: val-val; met-met) x 2 (Drug Order) 
x 2 (Test Version Order)
 
mixed-model MANOVA, as well as with corresponding ANOVAs for each of 
the 13 measures.  Neither the multivariate test for COMT moderation was significant, ( F (5, 1) = .64, 
p = .73), nor any of the univariate tests, p > 0.26 in all cases, with the exception of a significant Drug x 
COMT interaction on SAT Math (F (1, 11) = 13.06,  p < .00) which again complied with the predicted 
pattern of relatively greater enhancement for homozygous val than homozygous met participants (see 
Figure 4).  Additionally, a significant drug effect emerged on SAT Math: F (1, 11) = 5.63,  p = .04, 
although as shown Figure 4, this main effect of drug was an overall impairing effect. Main effects of 
COMT genotype were found for Word Recognition (F (1, 10) = 5.42, p = .04), along with borderline 
significant effects for Word Recall (F (1, 10) = 4.65,  p = .06), SAT Verbal (F (1, 11) = 4.24,  p = .06) 
and Object-2-Back Omissions (F (1, 10) = 4.22,  p = .07). The met-met genotype was associated with 
better performance than the val-val in all three cases.  
As with the analyses of baseline performance moderation, we followed up these analyses of 
genotype moderation with direct comparisons of drug and placebo performance in just the subjects for 
whom the drug would be expected, a priori, to be more helpful.  We first carried out a 2(Drug: MAS; 
Placebo) x 2 (Drug Order: MAS first; Placebo first) x 2 (Test Version Order: Version 1 first; Version 2 
first)
 
mixed-model MANOVA with repeated measures on the first factor and the 13 performance 
measures as the dependent variables.  The effect of MAS did not reach significance (F (2, 1) = .27, p = 
.81), nor did other effects or interactions, p > .49 in all cases. We then ran a series of 2 (Drug: MAS; 
Placebo) x 2 (Drug Order: MAS first; Placebo first) x 2 (Test Version Order: Version 1 first; Version 2 
first)
 
mixed-model ANOVAs with repeated measures on the first factor for each of the 13 measures 
only among the subsample homozygous for the val allele. The effect of the drug did not reach 
significance on any of the measures (all p’s > .24). See Supplementary Table 1 for other results which, 
because extraneous to our prediction, are not discussed further. 
In sum, as with the analysis of moderation by baseline performance, we found mixed evidence 
for the moderation by COMT: little evidence supported the predicted moderation but when such 
moderation was observed, it was generally consistent with the hypothesis of relatively greater 
enhancement in carriers of the val allele. 
 
3.4. Perceived enhancement 
We examined MAS’s effect on perceived enhancement through a 2 (Drug: MAS; Placebo) x2 
(Drug Order) x2 (Test Version Order) ANOVA, with repeated measures on the first factor. A main 
effect of drug (F (1, 40) = 4.09, p = .05) indicated that participants perceived MAS (M = 55.18, SD = 
14.87) as slightly more beneficial for cognitive performance than placebo (M = 50.25, SD = 3.95). 
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Although the earlier analyses demonstrate that MAS did not enhance cognition by any of the 
measures examined, it is nevertheless possible that subjective perceptions of enhancement are related 
to degree of true enhancement.  To test this, we correlated the difference in perceived enhancement 
between MAS and placebo, on the one hand, and the corresponding difference scores on each of our 11 
cognitive performance measures (no measure of perceived enhancement was administered during SAT 
Math and Verbal sessions). Ten of the 11 correlations did not reach statistical significance.  A 
significant correlation emerged between perceived and actual enhancement on Go/No-go (r = .33, p = 
.04).  To assess the relation between subjective perceptions and performance on all of the tasks 
together, we also created a composite of the differences between MAS and placebo sessions from each 
measure. This composite score did not correlate significantly with perceived enhancement: r = -.06, p 
= .76.  In sum, on average participants believed that the MAS had enhanced their cognitive 
performance more than placebo.  This perception stands in contrast to the reality: There was no actual 
enhancement on average nor were participants who felt more enhanced by the MAS more likely to 
show a true enhancement effect. 
 
4. Discussion 
4.1.Conclusions and relation to wider enhancement literature.   
Does MAS enhance cognition in healthy young adults? Our study was designed to overcome 
several challenges that have hampered previous attempts to answer this question.  It had sufficient 
power to detect a medium-size effect for any one measure of cognitive performance.  We nevertheless 
failed to find enhancement with any of the 13 measures we used.  Of course, a different drug or a 
different does of MAS have led to a different finding. Nevertheless, we can state that a standard 
clinical dose of a drug that is commonly used for cognitive enhancement did not enhance cognition in 
an adequately powered study. The most straightforward interpretation of these results is that MAS is 
not a powerful cognitive enhancer.  If it does enhance cognition in healthy and adequately-rested 
young adults, the effects are likely to be small. 
These findings raise the question of why many published studies find large effects of 
amphetamine on cognitive performance with tests of memory, executive function and other cognitive 
processes.  We believe that the answer is related to a set of problems, specifically low study power, 
flexibility in specific outcomes to be tested and publication bias against null results, which bedevil all 
branches of science, as explained in Ioannidis’s (2005) provocatively titled article, ―Why most 
published research findings are false.‖  The impact of these problems on psychology and neuroscience 
research, in the absence of any intentional malfeasance has been discussed by Ioannidis (2011), Lehrer 
(2010) and Simmons, Nelson & Simonsohn (2011) among others.  Research on cognitive enhancement 
is not particularly susceptible to these problems, compared to other research topics, but neither is it 
immune to them.  As a result, it is difficult to estimate the true robustness and effect size of cognitive 
enhancement with MAS and other stimulant medications by surveying the published literature.  
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On the assumption that the enhancing effects are real but are too small to be reliably captured 
in studies with sample sizes in the range typically used, one would expect a mix of positive and null 
results to be obtained.  Of course, those effects that are found would show relatively large effect sizes, 
because only those results that by chance err on the large side would achieve significance.  This is the 
pattern that we have seen in the literature, particularly regarding the effects of amphetamine on 
executive functions (Smith & Farah, 2011).  
In the present study we also tested the hypotheses that MAS is enhancing for subsets of healthy 
young adults, specifically those who are less cognitively capable or who are homozygous for the Val 
allele of the COMT gene.  Here too we generally failed to support these hypotheses, although a 
minority of specific statistical tests showed the predicted patterns. 
Finally, we found a small but reliable effect of MAS on judgments of enhancement, 
reminiscent of Davis’s (1947) observations of soldiers in World War II quoted earlier.  Participants 
believed themselves to be more enhanced by the pill when given MAS compared to placebo.  Although 
not apparent for every individual participant, the overall tendency was for participants to feel that their 
cognitive performance has been enhanced by MAS.  This may in part explain MAS’s popularity as a 
cognitive enhancer. 
4.2.Limitations of the present study.   
The present study was carefully designed to sample a wide array of cognitive abilities, to have 
adequate power and to measure potential moderators.  In other respects, however, its design leaves 
some important questions unanswered.  Most importantly, like most published studies in the 
enhancement literature (Smith & Farah, 2011), we did not vary drug dose and cannot know whether a 
higher or lower dose of the drug might have produced different results.  Similarly, we did not test the 
cognitive enhancing potential of other enhancers, such as methylphenidate and modafinil, leaving open 
the possibility that these drugs may significantly improve healthy people’s cognitive performance. We 
did not measure bioavailability of the drug (e.g., plasma amphetamine) and so cannot quantify how this 
varied across participants and sessions, for example as a function of individual differences in drug 
metabolism or food consumed before a session.  Different or more frequent assessments of the 
perceived effects of MAS might have revealed more nuanced results or measured perceived 
enhancement more reliably. Our participants were not representative of the general population; in 
addition to the restricted age range, they met a number of health and lifestyle criteria for inclusion, 
including never having used prescription stimulants and being low or moderate consumers of caffeine.  
Perhaps different results would have been obtained with people who have already self-selected to use 
stimulants or who enjoy large daily doses of caffeine. 
4.3.Implications for neuroethics.   
The present results have several implications for the neuroethics of cognitive enhancement.  
We believe that the issues of fairness, freedom and agency, discussed so extensively in the neuroethics 
literature (e.g., Farah, Illes, Cook-Deegan, Gardner, Kandel, King, Parens, Sahakian, & Wolpe, 2004) 
are not moot despite the present results.  It is of course true that the most thoughtful and incisive 
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ethical analysis is pointless if applied to an inaccurate representation of the empirical facts of the 
matter.  But we believe that Hall and Lucke (2010) are too dismissive of the realities of cognitive 
enhancement when they write ―Guidelines for enhancement prescription are … premature.  More 
skepticism needs to be expressed about neuroenhancement claims for pharmaceuticals and bioethicists 
should be much more cautious in … making proposals that will facilitate such use.‖ (p. 2042).  The 
present results suggest only that the effects of one currently available enhancement drug are small 
when measured in laboratory tests of memory, executive function and tests of intellectual aptitude.  
These results leave many questions unanswered. 
Among the important open questions are: How helpful might a small enhancement effect be 
over time? Might the effects be larger when measured under real-world conditions (e.g., with 
distractions in the environment or for longer and hence more tedious tasks than the typical memory or 
executive function experiment) or in a different state (e.g., after sleep deprivation)?  Does MAS exert a 
larger effect on other processes, such as motivation to work, which are not captured by laboratory 
studies of memory and executive function but which nevertheless impact academic and other cognitive 
work?  Or are users primarily attracted to this drug because of the illusory perception of enhancement 
our participants reported?  These are important questions for future research, which will furnish the 
needed empirical basis for discussions of enhancement ethics and policy. 
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Appendix 
Figure Captions 
Figure 1. Embedded Figures Task: An example stimulus. 
Figure 2. Experimental procedure. Each box corresponds to an individual testing session, with the time 
intervals between sessions indicated. Baseline testing (Sessions 2-3) always preceded 
drug/placebo testing (Sessions 4-7) to minimize the influence of practice effects on data from the 
placebo and MAS conditions. Each individual participant’s four on-pill sessions were scheduled at the 
same time of the day.  
Figure 3. Mean performance of participants whose overall baseline performance was below and above 
the median on Word Recall, Embedded Figures and Raven’s Progressive Matrices. Conventional error 
bars are not shown because the comparisons are within subjects.  
Figure 4. Mean performance of participants homozygous for the val and met allele of the COMT gene 
on SAT Math and SAT Verbal. Conventional error bars are not shown because the comparisons are 
within subjects.  
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